Diphosphonate therapy of paget's disease of bone.

Author: BohneW, CanfieldR, FeldmanF, KammermanS, KunigonisM, McWhorterJ, ResnickL, RosnerW, RyanK, SkinnerJ

Paper Details 
Original Abstract of the Article :
The use of disodium ethane-1 hydroxy-1, 1-diphosphonate (EHDP) therapy for Paget's disease of bone was examined in 75 affected patients. Forty-eight patients received randomly assigned oral doses of either 0, 2.5, 5, 10, or 20 mg/kg/day in a controlled, double-blind protocol, and the remainder recei...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1210/jcem-44-1-96

データ提供:米国国立医学図書館(NLM)

Diphosphonate Therapy for Paget's Disease of Bone: Optimizing Treatment Efficacy

Paget's disease of bone, a chronic condition characterized by abnormal bone remodeling, often requires treatment with diphosphonates. This study investigates the efficacy of disodium ethane-1 hydroxy-1, 1-diphosphonate (EHDP) therapy in patients with Paget's disease. Researchers conducted a controlled, double-blind study, assigning patients to receive different doses of EHDP or placebo. They evaluated the clinical status, urinary hydroxyproline levels, and serum alkaline phosphatase levels before and during treatment.

Optimizing EHDP Dosage for Maximum Benefit and Minimized Risk

The study found that EHDP therapy effectively reduced both urinary hydroxyproline and serum alkaline phosphatase levels, suggesting a beneficial effect on bone remodeling. However, patients receiving the higher doses of EHDP (10 or 20 mg/kg/day) had less favorable outcomes compared to those receiving lower doses (2.5 or 5 mg/kg/day). The higher dose group experienced a lower rate of symptom improvement and a higher rate of deterioration. Based on these findings, the researchers recommend an initial EHDP dose of 5 mg/kg/day to maximize benefits while minimizing potential adverse effects.

The Importance of Personalized Treatment for Paget's Disease

This research highlights the importance of individualized treatment strategies for Paget's disease, emphasizing the need for careful dose optimization to maximize benefits and minimize potential risks. Further studies are needed to investigate the long-term efficacy and safety of diphosphonate therapy in managing this chronic condition.

Dr.Camel's Conclusion

This research is like a camel caravan traversing a desert of bone, searching for the optimal treatment for Paget’s disease. It explores the efficacy of EHDP therapy and underscores the importance of personalized dosing to maximize benefits. It’s like discovering a hidden oasis in the desert – a reminder that careful planning and attention to detail are crucial for a successful journey.

Date :
  1. Date Completed 1977-03-21
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

401827

DOI: Digital Object Identifier

10.1210/jcem-44-1-96

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.